bluuebunny/crossref_metadata_2025 huggingface dataset:
Estimation of the Total Amount of Enhanced Rainfall for a Cloud Seeding Experiment: Case Studies of Preventing Forest Fire, Drought, and Dust
Authors: Ro Yonghun , Chang Ki-Ho , Chae Sanghee , Lim Yun-Kyu , Ku Jung Mo , Jung Woonseon
Published: July 2023

In this study, a method for verifying the effect of cloud seeding in the case of a mixture of natural and artificial rainfall bands was proposed, and its applicability to each experimental case was evaluated. Water resources that could be secured through cloud seeding were also quantified for the experiments on forest fire prevention, drought mitigation, and dust reduction in 2020. Data on numerical simulations, radar-derived rainfall, rain gauge-derived rainfall, and weather conditions were applied. Areas with seeding and nonseeding effects were classified according to the numerical simulation results and wind system, and enhanced rainfall was determined by comparing the changes in rainfall between the two areas. The amount of water resources was determined by considering the area of the seeding effect and rainfall density. As a result, 1.74 mm (4.75 million tons) of rainfall increased from the experiment on forest fire prevention, 0.84 mm (1.30 million tons) on drought mitigation, and 2.78 mm (24.44 million tons) on dust reduction. Thus, an average rainfall of 1.0 mm could be achieved through the experiment. These results helped verify the pure seeding effect and achieve the experimental purpose.
Seroprevalence of Peste des Petits Ruminants and Contagious Caprine Pleuropneumonia Coinfections in Goats in Kwale County, Kenya
Authors: Lugonzo George , Gitao George , Bebora Lilly , Lutta Harrison Osundwa
Published: July 2023

Goats are among the most important small ruminants affected by Peste des Petits ruminants (PPR) and contagious caprine pleuropneumonia (CCPP) diseases, two of the most significant constraints worldwide to the production of small ruminant species. Herein, the competitive enzyme‐linked immunosorbent assay (cELISA) and the latex agglutination test (LAT) were used to determine the coinfections of PPR and CCPP in goats in Kwale County on Kenya’s South Coast. A total of 368 serum samples were collected from goats of various ages and sexes exhibiting respiratory distress in the four subcounties of Kwale County (Kinango, Lunga Lunga, Matuga, and Msambweni) and screened for PPR and CCPP antibodies. Of the 368 goats sampled, 259 (70.4%) were females and 109 (29.6%) were males, and 126 (34.2%), 71 (19.3%), 108 (29.3%), and 63 (17.1%) samples were collected from Kinango, Matuga, Lunga Lunga, and Msambweni, respectively. The overall PPR seropositivity rate was 48.6% (179/368); rates in Kinango, Lunga Lunga, Matuga, and Msambweni were 70.6%, 29.6%, 49.3%, and 36.5%, respectively. The overall CCPP seropositivity rate was 45.4% (167/368), while rates in Kinango, Lunga Lunga, Matuga, and Msambweni were 51.6%, 49.1%, 36.6%, and 36.5%, respectively. Notably, the seropositivity of PPR was higher in male (53.3%) than in female (46.72%) goats, though not statistically significant. In addition, the CCPP seropositivity rates were not significantly different between male (44.0%) and female (45.9%) goats. Regarding age, the PPR seropositivity rates were 45.9%, 55.8%, and 52.3% in adults, kids, and weaners, respectively. For CCPP, the seropositivity rates were 48.3%, 40.4%, and 42.3% in adults, kids, and weaners, respectively. The coinfection rate of PPR and CCPP was 22.3% (82/368). Despite the high coinfection, univariate analysis revealed no relationship between PPR and CCPP infections. However, given the high PPR and CCPP infection rates, as a result of separate or coinfection, there is a need to upscale or intensify vaccination in the county.
Prevalence and Risk Factors of Trypanosomosis in Dromedary Camels in the Pastoral Areas of the Guji Zone in Ethiopia
Authors: Alemu Gossa , Abebe Rahmeto
Published: July 2023

Camel trypanosomosis is a life-threatening disease with adverse effects on camel health, production, and working efficiency. Despite this, camel trypanosomosis has received much less attention in Ethiopia compared with the disease in cattle and other animals. This cross-sectional study was conducted to evaluate the prevalence of camel trypanosomosis, identify the potential risk factors, and determine the importance of trypanosomosis in causing anemia in camels in the Gorodola and Liben districts in the Guji Zone of Oromia Regional State in Ethiopia. To this end, blood samples were collected from randomly selected 450 camels in heparinized capillary tubes and analyzed for the presence of Trypanosoma evansi using the buffy coat technique and Giemsa-stained thin smears. T. evansi infection was detected in 24 (5.3%) of the 450 camels examined. Out of the four variables analyzed in this study, two factors, such as body condition (BC) score and age, were found to be significantly (

P
<
0.05

) associated with trypanosomosis in camels. A higher prevalence of trypanosomosis was observed in camels in poor BC (13.22%) than in camels in good (4.62%) or moderate (1.01%) BC. Likewise, adult camels (8.09%) were infected more frequently than young camels (1.12%), whereas no trypanosomes were detected in camel calves under 2 years of age. No significant statistical difference was found between the two districts, and male and female camels (

P
>
0.05

). Statistically, the mean packed cell volume was significantly lower (

P
<
0.05

) in parasitemic camels (

26.5
%
±
7

) as compared with aparasitemic camels (

33.9
%
±
9.1

). In conclusion, the current study conducted during a dry season showed a moderate prevalence of trypanosomosis in camels. Further studies using more sensitive and specific diagnostic tests, such as miniature anion-exchange centrifugation technique, serology, or molecular tests, are needed to establish a true epidemiological dataset on the prevalence and seasonality of the disease and its vectors in the study area to recommend viable control measures.
Modeling and Design of ANFIS Dynamic Sliding Mode Controller for a Knee Orthosis of Hemiplegia
Authors: Eshetu Belay , Seid Solomon
Published: July 2023

The use of assistive devices to control the loss of strength and range of motion of hemiplegic patients is becoming common. It is difficult to develop a precise control approach for a knee orthosis system because of the unpredictability of the dynamics and the unwanted subject’s spasm, jerk, and vibration during gait assistance. In this study, an adaptive neuro-fuzzy inference system (ANFIS) control system based on a nonlinear disturbance observer (NDO) and dynamic sliding mode controller (DSMC) is presented to restore the natural gait of hemiplegic patients experiencing mobility disorder and strength loss as well as monitor patient-induced disturbances and parameter variations during semiactive assistance of both the stance and swing phases. The knee orthosis system’s nonlinear dynamic relations are first developed using the Euler–Lagrange formation. Using MATLAB/Simulink, the dynamic model and controller design for the knee orthosis system was created. The Lyapunov theory is then used to ensure the knee orthosis system is asymptotically stable in view of the proposed controller once the proposed control scheme has been designed. The proposed control scheme’s (ANFIS–NDO–DSMC) gait tracking performances are shown and contrasted with the conventional sliding mode controller (SMC). Furthermore, a comparative performance analysis for parametric uncertainties and disturbances is presented to look at the robustness of the proposed controller (ANFIS–NDO–DSMC). The coefficient of determination (

R

2

) and root mean square error (RMSE) between the reference knee angle and ANFIS–NDO–DSMC for stance phase are 1 and 0.000516 rad, respectively. For swing phase,

R

2

and RMSE are 0.9999 and 0.003202 rad, respectively. For SMC, RMSE is 0.000643 and 0.003252 rad for stance and swing phases, respectively. Stance and swing phase

R

2

is 0.9997 and 0.9994, respectively. As seen from simulation results, the proposed controller exhibited excellent gait tracking performance for the knee orthosis control with high robustness and very fast convergence to a steady state compared to SMC.
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Authors: Jackson Evangeline R. , Duchatel Ryan J. , Staudt Dilana E. , Persson Mika L. , Mannan Abdul , Yadavilli Sridevi , Parackal Sarah , Game Shaye , Chong Wai Chin , Jayasekara W. Samantha N. , Grand Marion Le , Kearney Padraic S. , Douglas Alicia M. , Findlay Izac J. , Germon Zacary P. , McEwen Holly P. , Beitaki Tyrone S. , Patabendige Adjanie , Skerrett-Byrne David A. , Nixon Brett , Smith Nathan D. , Day Bryan , Manoharan Neevika , Nagabushan Sumanth , Hansford Jordan R. , Govender Dinisha , McCowage Geoff B. , Firestein Ron , Howlett Meegan , Endersby Raelene , Gottardo Nicholas G. , Alvaro Frank , Waszak Sebastian M. , Larsen Martin R. , Colino-Sanguino Yolanda , Valdes-Mora Fatima , Rakotomalala Andria , Meignan Samuel , Pasquier Eddy , André Nicolas , Hulleman Esther , Eisenstat David D. , Vitanza Nicholas A. , Nazarian Javad , Koschmann Carl , Mueller Sabine , Cain Jason E. , Dun Matthew D.
Published: July 2023

All Supplementary Tables
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Authors: Jackson Evangeline R. , Duchatel Ryan J. , Staudt Dilana E. , Persson Mika L. , Mannan Abdul , Yadavilli Sridevi , Parackal Sarah , Game Shaye , Chong Wai Chin , Jayasekara W. Samantha N. , Grand Marion Le , Kearney Padraic S. , Douglas Alicia M. , Findlay Izac J. , Germon Zacary P. , McEwen Holly P. , Beitaki Tyrone S. , Patabendige Adjanie , Skerrett-Byrne David A. , Nixon Brett , Smith Nathan D. , Day Bryan , Manoharan Neevika , Nagabushan Sumanth , Hansford Jordan R. , Govender Dinisha , McCowage Geoff B. , Firestein Ron , Howlett Meegan , Endersby Raelene , Gottardo Nicholas G. , Alvaro Frank , Waszak Sebastian M. , Larsen Martin R. , Colino-Sanguino Yolanda , Valdes-Mora Fatima , Rakotomalala Andria , Meignan Samuel , Pasquier Eddy , André Nicolas , Hulleman Esther , Eisenstat David D. , Vitanza Nicholas A. , Nazarian Javad , Koschmann Carl , Mueller Sabine , Cain Jason E. , Dun Matthew D.
Published: July 2023

All Supplementary Figures and their captions.
Supplementary Figure Legends from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

The legends for supplementary figure 1-7.
Supplementary Figure 7 from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

RETSAT-RAR-SCD signaling pathway regulates ferroptosis via MUFA generation, and targeting retinoid metabolism might be a promising strategy in future cancer treatment.
Supplementary Figure 6 from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

RETSAT-RAR pathway promotes ferroptosis by activating SCD-mediated MUFA generation.
Supplementary Figure 4 from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

RETSAT links retinoid metabolism to ferroptosis.
Supplementary Figure 3 from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

RETSAT does not interfere with known ferroptosis regulators.
Supplementary Figure 2 from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

RETSAT is a pro-ferroptosis gene.
Supplementary Figure 1 from Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells
Authors: Bi Guoshu , Liang Jiaqi , Shan Guangyao , Bian Yunyi , Chen Zhencong , Huang Yiwei , Lu Tao , Li Ming , Besskaya Valeria , Zhao Mengnan , Fan Hong , Wang Qun , Gan Boyi , Zhan Cheng
Published: July 2023

Gating strategy and knockdown efficiency.
Supplemental Table from PTTG1 Reprograms Asparagine Metabolism to Promote Hepatocellular Carcinoma Progression
Authors: Zhou Qi , Li Leijia , Sha Feifei , Lei Yiming , Tian Xuan , Chen Lingjun , Chen Yan , Liu Huiling , Guo Yunwei
Published: July 2023

Supplemental Table
Supplemental Methods and Materials from PTTG1 Reprograms Asparagine Metabolism to Promote Hepatocellular Carcinoma Progression
Authors: Zhou Qi , Li Leijia , Sha Feifei , Lei Yiming , Tian Xuan , Chen Lingjun , Chen Yan , Liu Huiling , Guo Yunwei
Published: July 2023

Supplemental Methods and Materials
Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Authors: Bei Yuncheng , He Jian , Dong Xuhui , Wang Yuxin , Wang Sijie , Guo Wan , Cai Chengjie , Xu Zhiye , Wei Jia , Liu Baorui , Zhang Nan , Shen Pingping
Published: July 2023

serum biochemical parameters
Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
Authors: Bei Yuncheng , He Jian , Dong Xuhui , Wang Yuxin , Wang Sijie , Guo Wan , Cai Chengjie , Xu Zhiye , Wei Jia , Liu Baorui , Zhang Nan , Shen Pingping
Published: July 2023

gene signature correlated with exons of CD44v
Supplemental Information from Wnt Signaling Stimulates Cooperation between GREB1 and HNF4α to Promote Proliferation in Hepatocellular Carcinoma
Authors: Matsumoto Shinji , Harada Akikazu , Seta Minami , Akita Masayuki , Gon Hidetoshi , Fukumoto Takumi , Kikuchi Akira
Published: July 2023

Supplementary Methods.
Supplementary References.
Supplemental Figures 1-8 and associated legends.
Supplemental Tables 1-10.
Table S1 from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

Table S1 included primers used in real-time PCR
Supplementary Figure legends from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

This file contains the legends of supplementary figures.
Supplementary Data from Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
Authors: Pizzutilo Elio Gregory , Romanò Rebecca , Roazzi Laura , Agostara Alberto G. , Oresti Sara , Zeppellini Annalisa , Giannetta Laura , Cerea Giulio , Signorelli Diego , Siena Salvatore , Sartore-Bianchi Andrea
Published: July 2023

Appendix
Figure S5 from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

Figure S5 presents the results of luciferase assay in 293T cell.
Figure S4 from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

Figure S4 is the validation of SLC7A5 knockdown at protein level.
Figure S3 from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

Figure S3 describes that lack of tryptophan impairs the function of CD8+T cells.
Figure S2 from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

Figure S2 decribes enrichment of metabolic activities in immune cell tpes.
Figure S1 from Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer
Authors: Huang Xiaowen , Sun Tiantian , Wang Jilin , Hong Xialu , Chen Huimin , Yan Tingting , Zhou Chengbei , Sun Danfeng , Yang Chen , Yu TaChung , Su Wenyu , Du Wan , Xiong Hua
Published: July 2023

Figure S1 describes the workflow for scRNA-seq analysis and markers for celltype annotation.
Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Authors: Chachad Dhruv , Patel Lalit R. , Recio Carlos Vera , Pourebrahim Rasoul , Whitley Elizabeth M. , Wang Wenyi , Su Xiaoping , Xu An , Lee Dung-Fang , Lozano Guillermina
Published: July 2023

Pulmonary metastasis in p53 mutant mice
Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Authors: Chachad Dhruv , Patel Lalit R. , Recio Carlos Vera , Pourebrahim Rasoul , Whitley Elizabeth M. , Wang Wenyi , Su Xiaoping , Xu An , Lee Dung-Fang , Lozano Guillermina
Published: July 2023

List of mice belonging to different cohorts
Table S3 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Bulk RNAseq data
Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Authors: Chachad Dhruv , Patel Lalit R. , Recio Carlos Vera , Pourebrahim Rasoul , Whitley Elizabeth M. , Wang Wenyi , Su Xiaoping , Xu An , Lee Dung-Fang , Lozano Guillermina
Published: July 2023

List of primers used in genotyping and qRT-PCR experiments
Supplementary Figures from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Authors: Chachad Dhruv , Patel Lalit R. , Recio Carlos Vera , Pourebrahim Rasoul , Whitley Elizabeth M. , Wang Wenyi , Su Xiaoping , Xu An , Lee Dung-Fang , Lozano Guillermina
Published: July 2023

Supplementary Figures 1-6 with figure legends
Table S1 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Antibodies used for immunostaining and flow cytometry
Figure S5 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Lymphocyte and myeloid population profiles from resistant control and Ccr2RFP/RFP tumors.
Figure S3 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Ccr2 infiltration does not impact the growth of TBP tumors in an untreated setting.
Figure S2 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Representative flow cytometry plot showing gating strategies for identifying monocytes in blood and macrophages in TBP tumors.
Figure S1 from Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma
Authors: Kim Dahihm , An Luye , Moon Jiwon , Maymi Viviana I. , McGurk Alexander I. , Rudd Brian D. , Fowell Deborah J. , White Andrew C.
Published: July 2023

Tyr-CreER, LSL-BrafV600E, Ptenflox/flox genetically engineered mouse model (TBP GEMM).
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Authors: Hermida-Prado Francisco , Xie Yingtian , Sherman Shira , Nagy Zsuzsanna , Russo Douglas , Akhshi Tara , Chu Zhengtao , Feit Avery , Campisi Marco , Chen Minyue , Nardone Agostina , Guarducci Cristina , Lim Klothilda , Font-Tello Alba , Lee Irene , García-Pedrero Juana , Cañadas Israel , Agudo Judith , Huang Ying , Sella Tal , Jin Qingchun , Tayob Nabihah , Mittendorf Elizabeth A. , Tolaney Sara M. , Qiu Xintao , Long Henry , Symmans William F. , Lin Jia-Ren , Santagata Sandro , Bedrosian Isabelle , Yardley Denise A. , Mayer Ingrid A. , Richardson Edward T. , Oliveira Giacomo , Wu Catherine J. , Schuster Eugene F. , Dowsett Mitch , Welm Alana L. , Barbie David , Metzger Otto , Jeselsohn Rinath
Published: July 2023

Immunotherapies have yet to demonstrate significant efficacy in the treatment of hormone receptor–positive (HR+) breast cancer. Given that endocrine therapy (ET) is the primary approach for treating HR+ breast cancer, we investigated the effects of ET on the tumor immune microenvironment (TME) in HR+ breast cancer. Spatial proteomics of primary HR+ breast cancer samples obtained at baseline and after ET from patients enrolled in a neoadjuvant clinical trial (NCT02764541) indicated that ET upregulated β2-microglobulin and influenced the TME in a manner that promotes enhanced immunogenicity. To gain a deeper understanding of the underlying mechanisms, the intrinsic effects of ET on cancer cells were explored, which revealed that ET plays a crucial role in facilitating the chromatin binding of RelA, a key component of the NF-κB complex. Consequently, heightened NF-κB signaling enhanced the response to interferon-gamma, leading to the upregulation of β2-microglobulin and other antigen presentation-related genes. Further, modulation of NF-κB signaling using a SMAC mimetic in conjunction with ET augmented T-cell migration and enhanced MHC-I-specific T-cell–mediated cytotoxicity. Remarkably, the combination of ET and SMAC mimetics, which also blocks prosurvival effects of NF-κB signaling through the degradation of inhibitors of apoptosis proteins, elicited tumor regression through cell autonomous mechanisms, providing additional support for their combined use in HR+ breast cancer.

Significance:

Adding SMAC mimetics to endocrine therapy enhances tumor regression in a cell autonomous manner while increasing tumor immunogenicity, indicating that this combination could be an effective treatment for HR+ patients with breast cancer.
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Authors: Dalmat Ronit R. , Ziebell Rebecca A. , Kamineni Aruna , Phipps Amanda I. , Weiss Noel S. , Breslau Erica S. , Burnett-Hartman Andrea N. , Corley Douglas A. , Doria-Rose V. Paul , Green Beverly B. , Halm Ethan A. , Levin Theodore R. , Schottinger Joanne E. , Chubak Jessica
Published: July 2023

Background:

Colorectal cancer screening is universally recommended for adults ages 45 to 75 years. Noninvasive fecal occult blood tests are effective screening tests recommended by guidelines. However, empirical evidence to inform older adults’ decisions about whether to continue screening is sparse, especially for individuals with prior screening.

Methods:

This study used a retrospective cohort of older adults at three Kaiser Permanente integrated healthcare systems (Northern California, Southern California, Washington) and Parkland Health. Beginning 1 year following a negative stool-based screening test, cumulative risks of colorectal cancer incidence, colorectal cancer mortality (accounting for deaths from other causes), and non-colorectal cancer mortality were estimated.

Results:

Cumulative incidence of colorectal cancer in screen-eligible adults ages 76 to 85 with a negative fecal occult blood test 1 year ago (N = 118,269) was 0.23% [95% confidence interval (CI), 0.20%–0.26%] after 2 years and 1.21% (95% CI, 1.13%–1.30%) after 8 years. Cumulative colorectal cancer mortality was 0.03% (95% CI, 0.02%–0.04%) after 2 years and 0.33% (95% CI, 0.28%–0.39%) after 8 years. Cumulative risk of death from non-colorectal cancer causes was 4.81% (95% CI, 4.68%–4.96%) after 2 years and 28.40% (95% CI, 27.95%–28.85%) after 8 years.

Conclusions:

Among 76- to 85-year-olds with a recent negative stool-based test, cumulative colorectal cancer incidence and mortality estimates were low, especially within 2 years; death from other causes was over 100 times more likely than death from colorectal cancer.

Impact:

These findings of low absolute colorectal cancer risk, and comparatively higher risk of death from other causes, can inform decision-making regarding whether and when to continue colorectal cancer screening beyond age 75 among screen-eligible adults.
Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Authors: Allan John N. , Flinn Ian W. , Siddiqi Tanya , Ghia Paolo , Tam Constantine S. , Kipps Thomas J. , Barr Paul M. , Elinder Camburn Anna , Tedeschi Alessandra , Badoux Xavier C. , Jacobs Ryan , Kuss Bryone J. , Trentin Livio , Zhou Cathy , Szoke Anita , Abbazio Christopher , Wierda William G.
Published: July 2023

Supplementary Table S2. Sensitivity analysis of outcomes in patients with versus without high-risk features, excluding patients from the CAPTIVATE MRD cohort placebo arm
Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Authors: Allan John N. , Flinn Ian W. , Siddiqi Tanya , Ghia Paolo , Tam Constantine S. , Kipps Thomas J. , Barr Paul M. , Elinder Camburn Anna , Tedeschi Alessandra , Badoux Xavier C. , Jacobs Ryan , Kuss Bryone J. , Trentin Livio , Zhou Cathy , Szoke Anita , Abbazio Christopher , Wierda William G.
Published: July 2023

Supplementary Figure S1. Kaplan-Meier curves of progression-free survival (A) and overall survival (B) in the total pooled population of patients treated with fixed-duration ibrutinib plus venetoclax in the FD cohort and the MRD cohort placebo arm. Tick marks indicate censored patients.
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S7: GO analysis of the BioID assay.
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S6: Hits from the EPHA2 BioID assay.
Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Summary of baseline characteristics’ distribution between patients on other oral antidiabetic drugs/insulin only and those who were not on diabetes medications.
Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S4: Hits from the genome-wide shRNA screen in αEPHA2-Cond cells.
Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.
Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S2: Protein phosphorylation events distinct in αEPHA2-Cond and cIgG-Tr cells.
Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Summary of baseline characteristics’ distribution between patients on metformin only and those who were not on diabetes medications.
Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Table S1: Phosphorylated proteins expressed differently in αEPHA2-Cond and cIgG-Tr cells.
Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).
Supplementary Materials and Methods1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

-Supplementary Materials
Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Fig. S6. EPHA2, c-MET and EGFR levels in human tumors.
Figure S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Fig. S4. A. Heatmap of the shRNA screen hits that are enriched in the top 15 GO processesgenerated using GSEA software. B. Gene Set Enrichment Analysis plots of the top 15 GOprocess for the shRNA screen data produced by GSEA software used to generate the heatmap inA.
Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Summary of baseline characteristics of patients included in the targeted transcriptome analysis.
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Authors: El Zawily Amr , Vizeacoumar Frederick S. , Dahiya Renuka , Banerjee Sara L. , Bhanumathy Kalpana K. , Elhasasna Hussain , Hanover Glinton , Sharpe Jessica C. , Sanchez Malkon G. , Greidanus Paul , Stacey R. Greg , Moon Kyung-Mee , Alexandrov Ilya , Himanen Juha P. , Nikolov Dimitar B. , Fonge Humphrey , White Aaron P. , Foster Leonard J. , Wang Bingcheng , Toosi Behzad M. , Bisson Nicolas , Mirzabekov Tajib A. , Vizeacoumar Franco J. , Freywald Andrew
Published: July 2023

Fig. S3. A. Correlation cluster for both the replicates and different timepoints of the screeningdata. B. Fold-change distribution from the normalized shRNA intensity for the αEPHA2-Condand cIgG-Tr cells at different time points. C. Precision-recall curves after applying BAGELalgorithm to the screening data. F measure provided in the inset represents the harmonic mean ofprecision & recall of the screen.
Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.
Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Tumour micron-environment transcriptome analysis.
Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Authors: Cortellini Alessio , D'Alessio Antonio , Cleary Siobhan , Buti Sebastiano , Bersanelli Melissa , Bordi Paola , Tonini Giuseppe , Vincenzi Bruno , Tucci Marco , Russo Alessandro , Pantano Francesco , Russano Marco , Stucci Luigia Stefania , Sergi Maria Chiara , Falconi Martina , Zarzana Maria Antonietta , Santini Daniele , Spagnolo Francesco , Tanda Enrica T. , Rastelli Francesca , Giorgi Francesca Chiara , Pergolesi Federica , Giusti Raffaele , Filetti Marco , Lo Bianco Francesca , Marchetti Paolo , Botticelli Andrea , Gelibter Alain , Siringo Marco , Ferrari Marco , Marconcini Riccardo , Vitale Maria Giuseppa , Nicolardi Linda , Chiari Rita , Ghidini Michele , Nigro Olga , Grossi Francesco , De Tursi Michele , Di Marino Pietro , Queirolo Paola , Bracarda Sergio , Macrini Serena , Inno Alessandro , Zoratto Federica , Veltri Enzo , Spoto Chiara , Vitale Maria Grazia , Cannita Katia , Gennari Alessandra , Morganstein Daniel L. , Mallardo Domenico , Nibid Lorenzo , Sabarese Giovanna , Brunetti Leonardo , Perrone Giuseppe , Ascierto Paolo A. , Ficorella Corrado , Pinato David J.
Published: July 2023

Volcano plot of differentially regulated genes identified by Nanostring analysis. The Benjamini–Hockberg P-values are correlated to fold-changes in transcripts identified in diabetic samples (n = 11) versus non-diabetic controls (n = 11). The transcripts achieving the highest statistical significance (p value <0.05) are highlighted by the presence of the corresponding gene name. Significantly downregulated transcripts: HRAS, Ras oncogene family (p=0.009); GTF3C1, transcription factor of the TFIIIC complex (p=0.018); LAG3, key immune checkpoint for T cell modulation (p=0.023); BIRC5, survivin – modulator of programmed cell death (p=0.038); CXCL9 (p=0.038) and CXCL11 (p=0.048), two chemokines mediating inflammatory response; OAS3, interferon-induced enzyme (p=0.04). Significantly upregulated transcripts: IL22RA1, cytokine receptor (p=0.01); MME, transmembrane glycoprotein (p=0.02).
Supplementary Table S2 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma
Authors: Foote Michael B. , Walch Henry , Kemel Yelena , Vakiani Efsevia , Johannet Paul , Sheehan Margaret , Chatila Walid , Chung Sebastian , Nash Garrett M. , Maio Anna , Shia Jinru , Mandelker Diana , Berger Michael , Schultz Nikolaus , Diaz Luis A. , Cercek Andrea , Stadler Zsofia K.
Published: July 2023

Germline mutations present in the assessed cohort of patients with appendiceal adenocarcinoma.
Supplementary Figure S2 from The Impact of Germline Alterations in Appendiceal Adenocarcinoma
Authors: Foote Michael B. , Walch Henry , Kemel Yelena , Vakiani Efsevia , Johannet Paul , Sheehan Margaret , Chatila Walid , Chung Sebastian , Nash Garrett M. , Maio Anna , Shia Jinru , Mandelker Diana , Berger Michael , Schultz Nikolaus , Diaz Luis A. , Cercek Andrea , Stadler Zsofia K.
Published: July 2023

Appendix cancer specific survival in patients with stage IV appendiceal adenocarcinoma stratified by presence of a germline variant in CHEK2 (n=3) or BRCA1(n=1) associated with homologous recombination deficiency (HRD). Patients with germline variants in non-HRD-associated genes were not included in the analysis. Highlighted Kaplan Meier curve areas display the 95% confidence interval for the respective survival curves.